Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IMCY-0141 in RR-MS
NCT05417269Phase 2Active, not recruiting
- Sponsor
- Imcyse
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IMCY-0141 in relapsing-remitting multiple sclerosis (RRMS) (8 arms), sponsored by Imcyse. Primary endpoints: Solicited injection site and systemic Adverse Events at 36 weeks, All Serious Adverse Events at 36 weeks and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
IMCY-0141
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05417269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417269.